Stada Expands In MENA And APAC As Emerging Markets Strategy Pays Dividends

Germany's Stada Arzneimittel has secured the rights to market the FITO self-care medical device in the Gulf Cooperation Council region, North Africa, the Middle East and selected Asian Countries, and the Nizoral antifungal cream in Vietnam, the Philippines and Thailand. Stada’s half-year results show that the company’s emerging markets strategy is delivering results, with  MENA and APAC contributing to the growth recorded by the Consumer Healthcare division.

Emerging markets display screen graphics
• Source: Shutterstock

Stada Arzneimittel is further expanding its footprint in the Middle East and North Africa (MENA) and Asia Pacific (APAC) regions with two recently penned deals.

More from Asia

More from Geography

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By 

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.

Thai TikTok Boom Driving Double-Digit Growth In Southeast Asia’s Dietary Supplements Market

 
• By 

TikTok dietary supplement sales in Thailand grew by an astonishing 635% in 2024, while sales via Vietnam's and Malaysia's traditional e-commerce platforms increased by a still impressive 73% and 83% respectively.

New Product Launches Ensured Growth For Stada CHC In 2024

 
• By 

Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.